Board Sets 1:15 Ratio for Reverse Stock Split ATLANTA, June 4 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (NASDAQ:VEGF), a development...
ATLANTA, May 29 /PRNewswire-FirstCall/ -- Corautus Genetics, Inc. (NASDAQ:VEGF) announced today that, as expected, it received a letter dated...
Focus is on Compounds that Target Inflammation in the Blood Vessel Wall ATLANTA and SAN FRANCISCO, Feb. 8 /PRNewswire-FirstCall/ -- Corautus...
ATLANTA, Jan. 17 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (NASDAQ:VEGF) announced today that, in accordance with its previously stated...
ATLANTA, Dec. 14 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (NASDAQ:VEGF) ("Corautus") received a notification dated December 8, 2006...
Conference call to begin at 10:00 a.m. Eastern Time today ATLANTA, Nov. 14 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (NASDAQ:VEGF), a...
ATLANTA, Nov. 7 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (NASDAQ:VEGF), a development stage company dedicated to the development of...
ATLANTA, Nov. 3 /PRNewswire-FirstCall/ -- Corautus Genetics, Inc. (NASDAQ:VEGF) announced today that at this time it does not plan to conduct...
ATLANTA, Oct. 10 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (NASDAQ:VEGF), a clinical stage biopharmaceutical company, announced today...
Conference call to begin at 11:00 a.m. Eastern Time today ATLANTA, Aug. 10 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (NASDAQ:VEGF), a...
ATLANTA, Aug. 8 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (NASDAQ:VEGF), a biopharmaceutical company dedicated to the development of...
ATLANTA, July 13 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (NASDAQ:VEGF), a clinical stage biopharmaceutical company, announced today...
ATLANTA, July 6 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (NASDAQ:VEGF), a clinical stage biopharmaceutical company dedicated to the...
ATLANTA, June 20 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (NASDAQ:VEGF), a clinical stage biopharmaceutical company dedicated to the...
ATLANTA, May 31 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (NASDAQ:VEGF), a clinical stage biopharmaceutical company dedicated to the...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.